Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...
Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms
Amgen Inc.’s stock AMGN tumbled 7.8% in early trade Tuesday, after the company said a mid-stage trial of its weight-loss ...
Amgen’s stock slides 7.8% after weight-loss drug data lags analyst expectations
Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...
Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.
Amgen stock was dropping in premarket trading after releasing data from a Phase 2 study for its experimental weight-loss drug ...
Amgen Falls as Weight-Loss Shot Results Disappoint Street
Amgen Inc. shares fell the most in 23 years after its experimental obesity shot failed to significantly outperform rivals and ...
Weight-Loss Drugs Like Ozempic Would Be Covered By Medicare And Medicaid Under Biden Plan
Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden ...
Amgen shows 20% weight loss in once-monthly injectable MariTide
Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...
BioSpace15h
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
Amgen’s MariTide results are at the lower end of investors’ expectation of 20% to 25% weight loss. The much-anticipated ...